Kura Oncology Highlights Preclinical Data Demonstrating Potential of Farnesyl Transferase Inhibitors to Overcome Drug Resistance in Combination with Key Targeted Therapies Across Multiple Tumor TypesGlobeNewsWire • 09/16/25
Kura Oncology, Inc. (KURA) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)Seeking Alpha • 09/10/25
Kura Oncology to Host Virtual Investor and Analyst Events on Farnesyl Transferase Inhibitor ProgramGlobeNewsWire • 09/03/25
Kura Oncology: Ziftomenib Shift Towards Newly Diagnosed Mutant AML Patients Bodes WellSeeking Alpha • 07/02/25
Kura Oncology and Kyowa Kirin Report Positive Updated Combination Data for Ziftomenib in Newly Diagnosed AML at 2025 European Hematology Association CongressGlobeNewsWire • 06/12/25
Kura Oncology and Kyowa Kirin Report Positive Pivotal Ziftomenib Monotherapy Data at 2025 ASCO Annual MeetingGlobeNewsWire • 06/02/25
Kura Oncology and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib in Adults with Relapsed or Refractory NPM1-Mutant AMLGlobeNewsWire • 06/01/25
Kura Oncology and Kyowa Kirin Announce Pivotal Monotherapy Data for Ziftomenib in Oral Presentation at the 2025 ASCO Annual MeetingGlobeNewsWire • 05/22/25
Kura Oncology and Kyowa Kirin Announce Combination Data for Ziftomenib in Oral Presentation at the 2025 European Hematology Association (EHA) CongressGlobeNewsWire • 05/14/25
Kura Oncology Announces First Patients Dosed in Phase 1 Combination Trial of Ziftomenib for the Treatment of Advanced GISTGlobeNewsWire • 04/28/25
Kura Oncology and Kyowa Kirin Announce Submission of New Drug Application for Ziftomenib to FDAGlobeNewsWire • 04/08/25
Kura Oncology Announces Preclinical Data for KO-2806 Selected for Oral Presentation at the 2025 AACR Annual MeetingGlobeNewsWire • 03/26/25